Danes check low-risk devices
This article was originally published in Clinica
The Danish Medicines Agency, responsible for medical devices, has launched a surveillance programme for class I (low-risk) medical devices. These products are not subject to third-party certification by a notified body unless they are sterile or have a measuring function. The programme will involve spot-checks to ensure that manufacturers meet the requirements of the Medical Devices Directive (MDD), including product documentation requirements and setting up a post-market surveillance system.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.